Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Observational Study on Safety of BALFAXAR® vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure.

NCT06429787 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT06429787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06429787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Observational Study on Safety of BALFAXAR® vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure.
Lead sponsor
Octapharma
Phase
Observational
Overall status
Active, not recruiting
Start date
February 14, 2025
Completion date
June 30, 2032
Enrollment
3,574 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

significant bleeding risk, vitamin k-dependent coagulation defect